Trial Outcomes & Findings for Short-Term Clinical Comparison of Two Silicone Hydrogel Daily Disposable Contact Lenses (NCT NCT03139578)

NCT ID: NCT03139578

Last Updated: 2019-02-01

Results Overview

Overall lens fit acceptance was assessed by the investigator based on lens fitting characteristics and graded on a scale of 0 to 5, where 0=should not be worn and 5=perfect fit. The score ranges from 0 to 5, where higher scores indicate better fitting. The number of eye for each Grade was reported.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

51 participants

Primary outcome timeframe

30-45 minutes after lens settling

Results posted on

2019-02-01

Participant Flow

A total of 51 subjects were enrolled in the study from two sites. Of those enrolled, 50 subjects were randomized and 50 subjects were dispensed a study lens. All 50 subjects completed the study, while no one discontinued from the study.

Participant milestones

Participant milestones
Measure
C 8.5\C 9.0\T 8.5\T 9.0
Subjects randomized to this sequence received Control lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the first period and then received Test lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the second period.
C 9.0\C 8.5\T 9.0\T 8.5
Subjects randomized to this sequence received Control lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the first period and then received Test lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the second period.
T 8.5\T 9.0\C 8.5\C 9.0
Subjects randomized to this sequence received Test lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the first period and then received Control lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the second period.
T 9.0\T 8.5\C 9.0\C 8.5
Subjects randomized to this sequence received Test lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the first period and then received Control lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the second period.
Period 1
STARTED
12
13
12
13
Period 1
Discontinued
0
0
0
0
Period 1
COMPLETED
12
13
12
13
Period 1
NOT COMPLETED
0
0
0
0
Period 2
STARTED
12
13
12
13
Period 2
Discontinued
0
0
0
0
Period 2
COMPLETED
12
13
12
13
Period 2
NOT COMPLETED
0
0
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Short-Term Clinical Comparison of Two Silicone Hydrogel Daily Disposable Contact Lenses

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Total
n=50 Participants
All subjects who were administered any test article excluding subjects who drop out prior to administering any test article
Age, Continuous
30.3 years
STANDARD_DEVIATION 13.61 • n=5 Participants
Sex: Female, Male
Female
34 Participants
n=5 Participants
Sex: Female, Male
Male
16 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
47 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
14 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
3 Participants
n=5 Participants
Race (NIH/OMB)
White
20 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
13 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
Region of Enrollment
United Kingdom
50 Participants
n=5 Participants

PRIMARY outcome

Timeframe: 30-45 minutes after lens settling

Population: All subjects who had successfully completed all required assessments visits without any a major protocol deviations.

Overall lens fit acceptance was assessed by the investigator based on lens fitting characteristics and graded on a scale of 0 to 5, where 0=should not be worn and 5=perfect fit. The score ranges from 0 to 5, where higher scores indicate better fitting. The number of eye for each Grade was reported.

Outcome measures

Outcome measures
Measure
Test 8.5BC
n=48 Eyes
Subjects randomized to receive senofilcon A lens 8.5 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Test 9.0BC
n=48 Participants
Subjects randomized to receive senofilcon A lens 9.0 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Control 8.5BC
n=48 Eyes
Subjects randomized to receive narafilcon A lens 8.5 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Control 9.0BC
n=48 Eyes
Subjects randomized to receive narafilcon A lens 9.0 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Overall Fit Acceptance
0
0 Eyes
0 Eyes
0 Eyes
0 Eyes
Overall Fit Acceptance
1
0 Eyes
0 Eyes
0 Eyes
0 Eyes
Overall Fit Acceptance
2
1 Eyes
2 Eyes
1 Eyes
5 Eyes
Overall Fit Acceptance
3
5 Eyes
8 Eyes
5 Eyes
7 Eyes
Overall Fit Acceptance
4
17 Eyes
24 Eyes
19 Eyes
17 Eyes
Overall Fit Acceptance
5
25 Eyes
14 Eyes
23 Eyes
19 Eyes

PRIMARY outcome

Timeframe: 30-45 minutes after lens settling

Population: All subjects who had successfully completed all required assessments without a major protocol deviation.

The lens power requirements (aka sphere requirements) for each lens type was calculated by summing the lens power and the spherical over-refraction. Then the difference of lens power requirement between the Test and Control lenses was calculated (Test-Control).

Outcome measures

Outcome measures
Measure
Test 8.5BC
n=48 Eyes
Subjects randomized to receive senofilcon A lens 8.5 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Test 9.0BC
n=48 Eyes
Subjects randomized to receive senofilcon A lens 9.0 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Control 8.5BC
n=48 Eyes
Subjects randomized to receive narafilcon A lens 8.5 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Control 9.0BC
n=48 Eyes
Subjects randomized to receive narafilcon A lens 9.0 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Lens Power Requirement
<= -3.75
10 Eyes
9 Eyes
10 Eyes
8 Eyes
Lens Power Requirement
-3.50 to -3.00
7 Eyes
9 Eyes
7 Eyes
10 Eyes
Lens Power Requirement
-2.75 to -2.25
17 Eyes
15 Eyes
16 Eyes
15 Eyes
Lens Power Requirement
-2.00 t -1.50
9 Eyes
10 Eyes
10 Eyes
10 Eyes
Lens Power Requirement
-1.25 to -0.75
2 Eyes
2 Eyes
3 Eyes
2 Eyes
Lens Power Requirement
>= -0.50
3 Eyes
3 Eyes
2 Eyes
3 Eyes

SECONDARY outcome

Timeframe: Immediately upon lens insertion

Population: All subjects who had successfully completed all required assessments without a major protocol deviation.

Subjective comfort on insertion was assessed by the subject on an 11-point scale (0 to 10) where 0=painful and 10=can't be felt. The score ranges from 0 to 10, where higher scores indicate better comfort. The average comfort score for each lens was reported.

Outcome measures

Outcome measures
Measure
Test 8.5BC
n=48 Eyes
Subjects randomized to receive senofilcon A lens 8.5 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Test 9.0BC
n=48 Eyes
Subjects randomized to receive senofilcon A lens 9.0 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Control 8.5BC
n=48 Eyes
Subjects randomized to receive narafilcon A lens 8.5 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Control 9.0BC
n=48 Eyes
Subjects randomized to receive narafilcon A lens 9.0 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Subjective Comfort at Lens Insertion
9.15 Graded Scale 0-10
Standard Deviation 1.353
9.04 Graded Scale 0-10
Standard Deviation 1.220
8.92 Graded Scale 0-10
Standard Deviation 1.302
9.02 Graded Scale 0-10
Standard Deviation 1.176

SECONDARY outcome

Timeframe: 30-45 minutes after lens settling

Population: All subjects who had successfully completed all required assessments without a major protocol deviation.

Subjective comfort on setting was assessed by the subject on an 11-point scale (0 to 10) where 0=painful and 10=can't be felt. The score ranges from 0 to 10, where higher scores indicate better comfort. The average comfort score for each lens was reported.

Outcome measures

Outcome measures
Measure
Test 8.5BC
n=48 Eyes
Subjects randomized to receive senofilcon A lens 8.5 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Test 9.0BC
n=48 Eyes
Subjects randomized to receive senofilcon A lens 9.0 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Control 8.5BC
n=48 Eyes
Subjects randomized to receive narafilcon A lens 8.5 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Control 9.0BC
n=48 Eyes
Subjects randomized to receive narafilcon A lens 9.0 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Subjective Comfort After Lens Settling
9.50 Graded scale 0-10
Standard Deviation 0.715
9.27 Graded scale 0-10
Standard Deviation 1.005
9.56 Graded scale 0-10
Standard Deviation 0.769
9.13 Graded scale 0-10
Standard Deviation 1.214

SECONDARY outcome

Timeframe: 30-45 minutes after lens settling

Population: All subjects who had successfully completed all required assessments without a major protocol deviation.

Subjective vision quality was assessed by the subject on an 11-point scale (0 to 10) where 0=extremely blurred and 10=perfect. The score ranges from 0 to 10, where higher scores indicate better vision quality. The average vision quality score for each lens was reported.

Outcome measures

Outcome measures
Measure
Test 8.5BC
n=48 Eyes
Subjects randomized to receive senofilcon A lens 8.5 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Test 9.0BC
n=48 Eyes
Subjects randomized to receive senofilcon A lens 9.0 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Control 8.5BC
n=48 Eyes
Subjects randomized to receive narafilcon A lens 8.5 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Control 9.0BC
n=48 Eyes
Subjects randomized to receive narafilcon A lens 9.0 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Subjective Vision Quality
9.33 Graded scale 0-10
Standard Deviation 0.753
9.25 Graded scale 0-10
Standard Deviation 0.911
9.19 Graded scale 0-10
Standard Deviation 1.104
9.19 Graded scale 0-10
Standard Deviation 1.065

SECONDARY outcome

Timeframe: Immediately upon lens insertion

Population: All subjects who had successfully completed all required assessments without a major protocol deviation.

Subjective handling was assessed by the subject on an 11-point scale (0 to 10) where 0=extremely difficult and 10=very easy. The score ranges from 0 to 10, where higher scores indicate better handling. The average handling score for each lens was reported.

Outcome measures

Outcome measures
Measure
Test 8.5BC
n=48 Eyes
Subjects randomized to receive senofilcon A lens 8.5 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Test 9.0BC
n=48 Eyes
Subjects randomized to receive senofilcon A lens 9.0 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Control 8.5BC
n=48 Eyes
Subjects randomized to receive narafilcon A lens 8.5 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Control 9.0BC
n=48 Eyes
Subjects randomized to receive narafilcon A lens 9.0 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Subjective Handling
9.17 Graded scale 0-10
Standard Deviation 1.243
9.10 Graded scale 0-10
Standard Deviation 1.242
9.13 Graded scale 0-10
Standard Deviation 1.248
9.25 Graded scale 0-10
Standard Deviation 1.139

SECONDARY outcome

Timeframe: 30-45 minutes after lens settling

Population: All subjects who had successfully completed all required assessments without a major protocol deviation.

Monocular high contrast distance VA with the study lenses was collected to the nearest letter using computer generated logMAR charts. 0.02 logMAR is equivalent to 1 letter. Negative logMAR values indicate better lens performance. The average visual acuity was reported for each lens type.

Outcome measures

Outcome measures
Measure
Test 8.5BC
n=48 Eyes
Subjects randomized to receive senofilcon A lens 8.5 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Test 9.0BC
n=48 Eyes
Subjects randomized to receive senofilcon A lens 9.0 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Control 8.5BC
n=48 Eyes
Subjects randomized to receive narafilcon A lens 8.5 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Control 9.0BC
n=48 Eyes
Subjects randomized to receive narafilcon A lens 9.0 base curve in either the right or left eye and successfully completed all assessments without a major protocol deviation.
Monocular High Contrast Visual Acuity (VA)
-0.02 logMAR
Standard Deviation 0.068
-0.02 logMAR
Standard Deviation 0.083
-0.02 logMAR
Standard Deviation 0.064
-0.02 logMAR
Standard Deviation 0.061

Adverse Events

Test 8.5BC

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Test 9.0BC

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control 8.5BC

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control 9.0BC

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Anna Sulley BSc MCOptom FAAO

Johnson & Johnson Vision

Phone: +44 1344864043

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: GT60